Navigation Links
Vincent W. Renz Joins NewCardio as President

Industry Leader with Strong Clinical Research Relationships and Proven Track Record in Driving Growth Organizations to Lead Commercialization

SANTA CLARA, Calif., Aug. 18 /PRNewswire-FirstCall/ -- NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic and services company, today announced that Vincent W. Renz has joined NewCardio as its president. Mr. Renz will oversee the Company's commercialization effort, to include business development, client services, software development, and quality assurance. In addition, he will play a key role in developing strategic partnerships and alliances. Mr. Renz will report directly to Branislav Vajdic, Ph.D., who continues as the Company's Chief Executive Officer.

Mr. Renz has more than 26 years of experience in the information technology industry, specifically in the development and commercialization of technology products and services. He joins NewCardio from ClinPhone, the world's leading Clinical Technology Organization recently acquired by PAREXEL International Corporation, a leading global biopharmaceutical services organization. At ClinPhone, Mr. Renz served as Chief Operating Officer. Previously, he worked for eResearch Technology, Inc. as the Executive Vice President and Chief Technology Officer and played a key role in building eResearch Technology's clinical technology business. Mr. Renz was also instrumental in developing the global business development and client services infrastructure to support the company's rapid growth and profitability. Mr. Renz earned an M.B.A. in Management Information Systems from Indiana University and a B.B.A. in Finance from the University of Notre Dame.

Dr. Vajdic commented, "With the validation of QTinno(TM), our lead product, essentially complete, this announcement marks the first step in our aggressive commercialization effort. Adding an industry leader like Vinnie to our team is a win for NewCardio, its employees, customers and shareholders. He brings proven skills in the life Sciences, health care and information technology industries, with particular expertise in business development, partnership formation and support of innovative software-based technologies. He adds deep understanding of the clinical trials industry, product development life cycle, and the proven ability to create business development and customer service teams. This expertise should prove invaluable as we strive to add clinical and diagnostic value to the hundreds of millions of ECGs performed every year in health care settings, clinical trials and life screening settings."

Mr. Renz added, "It is clear to me that NewCardio's three-dimensional software platform has the potential to become a game changing technology with many applications targeting large, rapidly growing, underserved markets. As an example the Company's initial product, QTinno(TM), promises much-needed automation to replace a costly, labor-intensive process in cardiac safety assessment in clinical research; particularly in large scale thorough QT studies that are required for all compounds prior to FDA submission. I believe QTinno(TM) will be quickly embraced by drug sponsors who are looking to accelerate clinical trials and cut costs, while ensuring regulatory compliance. I also believe contract research organizations looking to expand their product and service offerings in order to increase margins and compete more effectively for market share will embrace the product, as well. Government regulators are also looking for processes which provide more precise, predictable and rapid data, as evidenced by the FDA's participation in the Cardiac Safety Research Consortium. Beyond this lead product, the technology has the potential to advance the diagnostic capability of the traditional electrocardiogram (ECG) to address a broader range of cardiac care to include patient monitoring, emergency room diagnosis, and life screening diagnosis by providing automated, high quality, assessment data and predictive markers generated through the company's proprietary technology that generates three-dimensional models for visual review. It's an exciting time to join NewCardio, and I look forward to leading the commercialization of this exciting technology platform."

About NewCardio, Inc.

NewCardio is a cardiac diagnostic and services company focused on the development of a proprietary platform technology to provide higher accuracy to, and increase the value of, the standard 12-lead electrocardiogram (ECG). NewCardio's development-stage software and hardware products and services are intended to improve the diagnosis and monitoring of cardiovascular disease (CVD), as well as cardiac safety assessment of drugs under development. NewCardio's three-dimensional ECG platform is designed to reduce the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. For more information, visit

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K/A (No. 1) for the year ended December 31, 2007 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.

To join our email distribution please click this link:

SOURCE NewCardio, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Judith Quinlan Joins Cytel as Vice President, Adaptive Trials
2. Dr. Peter Nash, Ph.D. Joins Mach One Corporation as Chief Scientist
3. Dr. Harriet Robinson Joins GeoVax Team as V.P. of R & D to Accelerate AIDS Vaccine Trials Program
4. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
5. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
6. Olympic Gold Medalist Kristi Yamaguchi Joins American Lung Association of Michigan to Address Seriously Low Vaccination Rates; Urge Metro-Detroiters to Get Immunized This Season
7. MedicAlert Foundation Joins The Alzheimers Association to Offer MedicAlert(R) + Alzheimers Association Safe Return(R) - Live 24-Hour Emergency Response for Wandering and Medical Emergencies
8. Actress and Mother Jennifer Garner Joins American Lung Association to Encourage Americans to Get an Influenza Vaccination
9. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
10. Actress and New Mom Keri Russell Joins PKIDs to launch Silence the Sounds of Pertussis Campaign
11. General Wesley Clark Joins Immtech as Consulting Strategic Advisor
Post Your Comments:
(Date:9/28/2017)... -- Cohen Veterans Bioscience and Early Signal Foundation announce ... home sensors for real-time monitoring of patients with trauma-related ... organization focused on disruptive health solutions for rare disorders ... to record and integrate behavioral, cognitive, physiological and contextual ... ...
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
(Date:9/18/2017)... KALAMAZOO, Mich. , Sept. 18, 2017 /PRNewswire/ ... and OptiMed Specialty Pharmacy of Kalamazoo, Mich. ... a strategic hub service that expedites and streamlines patient ... spirometer, Spiro PD 2.0, and wellness management services.  ... a medical device used to measure lung function for ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading ... Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly ... CBD form that can be easily incorporated into liquid products, while reducing costs to ...
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released ... understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture ... Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that is ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
Breaking Medicine News(10 mins):